Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + fluorouracil + lapatinib
- Development stage
- Unknown
- Lead developer
- Michigan State University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of cisplatin, fluorouracil, and lapatinib. Cisplatin is a platinum-based chemotherapy that forms DNA crosslinks disrupting cancer cell division. Fluorouracil (5-FU) is a pyrimidine analog that interferes with DNA synthesis by blocking thymidylate synthetase. Lapatinib is a dual inhibitor of HER2 and epidermal growth factor receptor (EGFR) tyrosine kinases.
02
Targets
DNAEGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on cisplatin + fluorouracil + lapatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + fluorouracil + lapatinib.